This inhibition is accompanied by a greater induction of apoptosis and reduced expression levels of EGFR, CD133, and Nestin, suggesting that honokiol might have clinical benefits for GBM patients, mainly those who are refractory to TMZ treatment [75, 173, 176]. The gene discussed is PROM1; the disease is glioblastoma.